Limited Transmission Potential of Takeda's Tetravalent Dengue Vaccine Candidate by Aedes albopictus

Recombinant live-attenuated chimeric tetravalent dengue vaccine viruses, TDV-1, -2, -3, and -4, contain the premembrane and envelope genes of dengue virus serotypes 1-4 in the replicative background of the attenuated dengue virus type-2 (DENV-2) PDK-53 vaccine strain. Previous results have shown tha...

Full description

Saved in:
Bibliographic Details
Published inThe American journal of tropical medicine and hygiene Vol. 97; no. 5; pp. 1423 - 1427
Main Authors Dietrich, Elizabeth A, Ong, Yee Tsuey, Stovall, Janae L, Dean, Hansi, Huang, Claire Y-H
Format Journal Article
LanguageEnglish
Published United States The American Society of Tropical Medicine and Hygiene 01.11.2017
Subjects
Aedes - virology
Animals
Cercopithecus aethiops
Dengue - immunology
Dengue - transmission
Dengue Vaccines - immunology
Dengue Virus - genetics
Female
Insect Vectors - virology
Logistic Models
Serogroup
Vaccines, Attenuated - immunology
Vero Cells
Online AccessGet full text

Cover

More Information
Summary:Recombinant live-attenuated chimeric tetravalent dengue vaccine viruses, TDV-1, -2, -3, and -4, contain the premembrane and envelope genes of dengue virus serotypes 1-4 in the replicative background of the attenuated dengue virus type-2 (DENV-2) PDK-53 vaccine strain. Previous results have shown that these recombinant vaccine viruses demonstrate limited infection and dissemination in and are unlikely to be transmitted by the primary mosquito vector of DENVs. In this report, we expand this analysis by assessing vector competence of all four serotypes of the TDV virus in , the secondary mosquito vector of DENVs. Our results indicate that these vaccine viruses demonstrate incompetence or defective infection and dissemination in these mosquitoes and will likely not be transmissible.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Authors’ addresses: Elizabeth A. Dietrich, Yee Tsuey Ong, Janae L. Stovall, and Claire Y.-H. Huang, Centers for Disease Control and Prevention, Division of Vector-Borne Diseases, Fort Collins, CO, E-mails: wul2@cdc.gov, yoe2@cdc.gov, tzr5@cdc.gov, and yxh0@cdc.gov. Hansi Dean, Takeda Vaccines, Inc., Cambridge, MA, E-mail: hansi.dean@takeda.com.
ISSN:0002-9637
1476-1645
DOI:10.4269/ajtmh.17-0185